other material
confidence high
sentiment positive
materiality 0.80
Milestone's etripamil Phase 2 meets primary endpoint; 30 bpm ventricular rate reduction vs placebo
Milestone Pharmaceuticals Inc.
- Mean ventricular rate reduction of 29.91 bpm vs placebo (p<0.0001); absolute max reduction 35 bpm etripamil vs 5 bpm placebo.
- 58.3% of etripamil patients achieved <100 bpm vs 4% placebo; median time to max reduction 13 min, effect ~150 min.
- TSQM-9 patient-reported symptom relief significantly improved: effectiveness (p<0.0001) and relief of symptoms (p=0.0002).
- Safety consistent with PSVT program; SAEs rare: one patient with transient severe bradycardia/syncope resolved.
- Company plans Phase 3 trial; NDA for etripamil in PSVT already submitted with FDA.